Molecular pathogenesis of malignant gliomas

Current Opinion in Oncology

Volumn 11, Issue 3, 1999, Pages 162-167

  Ahmed Rasheed, B K ^a   Wiltshire, Rodney N ^a   Bigner, Sandra H ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ASTROCYTOMA; CANCER GRADING; CHROMOSOME 10; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; DELETION MUTANT; GENE AMPLIFICATION; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR BIOLOGY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 10; GENE AMPLIFICATION; GENE DELETION; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0032943160     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199905000-00004     Document Type: Review

References (37)

1. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM: Tumors of central neuroepithelial origin. In Russell & Rubinstein's Pathology of Tumors of the Nervous System, vol 1, edn 6. Edited by Bigner DD, McLendon RE, Bruner JM. London: Arnold; 1998:307-571.
2. Kleihues P, Burger PC, Sheithauer BW: Histological Typing of Tumours of the Central Nervous System, edn 2. Berlin: Springer-Verlag; 1993.
3. Fulci G, Ishii N, Van Meir EG: p53 and Brain tumors: from gene mutations to gene therapy [review]. Brain Pathol 1998, 8:599-613.
4. Ishii N, Sawamura Y, Tada M, Daub DM, Janzer RC, Meagher-Villemure K, et al.: Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay. Int J Cancer 1998, 76:797-800.
5. Watanabe K, Pearud A, Gratas C, Wakai S, Kleihues P, Ohgaki H: p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 1998, 95:559-564. A high frequency (82%) of p53 mutations was seen in gemistocytic astrocytomas.
6. Li Y, Millikan RC, Carozza S, Newman B, Liu E, Davis R, et al.: p53 Mutations in malignant gliomas. Cancer Epidemiol Biomarkers Prev 1998, 7:303-308.
7. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or 3Bcl-2 genes. Brain Pathol 1998, 8:655-667. The status of several tumor suppressor and oncogenes was studied mainly by immunohistochemistry in a set of 80 glioblastoma patients of various age groups. Survival testing showed that altered expression of p16, p53, EGFR, MDM2, or Bcl-2 had no prognostic significance.
8. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H: Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 1998, 58:609-613.
9. Cavenee WK, Bigner DD, Newcomb EW, Paulus W, Kleihues P: Diffuse astrocytomas. In Pathology and Genetics of Tumours of the Nervous System. Edited by Kleihues P, Cavenee WK, Lyon: International Agency for Research on Cancer; 1997:2-9.
10. Sidransky M, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee WK, Vogelstein B: Clonal expansion of p53 mutant alleles is associated with brain tumour progression. Nature 1992, 355:846-847.
11. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997, 7:755-764.
12. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H: Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 1997, 94:303-309.
13. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN: Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998, 57:122-130. A comparison of molecular versus immunohistochemical method suggested that molecular methods were better in detecting p16 and RB abnormalities.
14. Hulsebos TJM, Oskam NT, Troost D, Leenstra S, Bijleveld EH: Dynamics of genetic alterations associated with glioma recurrence. Genes Chromosomes Cancer 1998, 23:153-158.
15. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al.: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998, 16:2259-2264. Mutations of in the PTEN gene were analyzed by SSCP sequencing in a series of 331 tumors. Mutations were rare among lower-grade tumors but occurred in approximately 20% of glioblastomas.
16. Wang SI, Puc J, Li J, Bruce JN, Cairns P, Sidransky D, Parsons R: Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997, 57:4183-4186.
17. Bostrom J, Cobbers JMJL, Wolter M, Tabatabai G, Weber RG, Lichter P, et al.: Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 1998, 58:29-33.
18. Chiariello E, Roz L, Albarosa R, Magnani I, Finocchiaro G: PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene 1998, 16:541-545.
19. Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, Van Meir EG, et al.: Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 1998, 16:3331-3335.
20. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al.:PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 1998, 57:684-689. Ten of 28 primary glioblastomas contained PTEN alteration compared with 1 of 25 secondary glioblastoma.
21. Steck PA, Lin H, Langford LA, Jasser SA, Koul D, Yung WKA, Pershouse MA: Functional and molecular analyses of 10q deletions in human gliomas. Genes Chromosomes Cancer 1999, 24:135-143. A model of molecular progression is discussed in which 10q25-26 LOH is an early event in the glioma tumorigenesis and is followed by the deletion of the PTEN/ during the progression to high-grade GBMs.
22. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al.: DMBT1 a new member of the SRCR superfamily on chromosome 10q25.3-26.1 is deleted in malignant brain tumors. Nat Genet 1997, 17:32-39.
23. Somerville RPT, Shoshan Y, Eng C, Barnett G, Miller D, Cowell JK: Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene 1998, 17:1755-1757.
24. Chernova OB, Somerville RPT, Cowell JK: A novel gene LGI1 from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene 1998, 17:2873-2881. Using positional cloning strategy a novel gene, LG11, involved in translocation in the T98G glioblastoma cell line was isolated. The gene is mapped to 10q24 and expressed in normal brain. It is a candidate tumor suppressor gene because rearrangements and loss of expression were seen in high-grade tumors.
25. Fults D., Pedone C.A., Thompson G.E., Uchiyama C.M., Gumpper K.L., Iliev D., et al. Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol 1998, 12:905-910.
26. Nakamura H, Yoshida M, Tsuiki H, Ito K, Ueno M, Nakao M, et al.:Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region. Oncogene 1998, 16:1009-1019.
27. Kon H, Sonoda Y, Kumabe T, Yoshimoto T, Sekiya T, Murakami Y: Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome in human gliomas. Oncogene 1998, 16:257-263.
28. Zhu JJ, Santarius T, Wu X, Tsong J, Guha A, Wu JK, et al.: Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosomes Cancer 1998, 21:207-216. Allelotyping analysis of 16 oligodendrogliomas detected LOH for 1p in 31% to 73% of the tumors and for 19q in 23% to 69% of the tumors. In 9 anaplastic oligodendrogliomas, LOH for 1p loci was found in 60% to 100% and for 19q in 100% of the cases.
29. Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, et al.: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997, 56:1098-1104.
30. Ross SM, van Deeken H, Krishnadath KK, Alers JC, Kros JM: Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 1997, 56:1125-1131.
31. Mai M, Huang H, Reed C, Qian C, Smith JS, Alderete B, et al.: Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1p arm deletions. Genomics 1998, 51:359-363.
32. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479. In anaplastic oligodendrogliomas, losses involving both 1p and 19q were strongly associated with longer over all survival and CDKN2A deletions and ring enhancement were associated with a significantly worse prognosis.
33. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD: The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 1998, 4:148-158.
34. Eley G, Frederick L, Wang XY, Smith DI, James CD: 3′ End structure and rearrangements of EGFR in glioblastomas. Genes Chromosomes Cancer 1998, 23:248-254. Rearrangements at the 3′ end of the EGFR gene was mapped at genomic DNA level, and the loss of exons 23 to 25 was seen.
35. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJS: Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3 like proteases. Proc Natl Acad Sci U S A 1998, 95:5724-5729.
36. Fischer U, Heckel D, Michel A, Janka M, Hulsebos T, Meese E: Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade 1. Human Mol Genet 1997, 6:1817-1822.
37. Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, et al.: GAC1 a new member of the lecucine-rich repeat superfamily on chromosome band 1q32.1 is amplified and overexpressed in malignant gliomas. Oncogene 1998, 16:2997-3002.